ScholarLens Back to search
2019•Lung Cancer Targets and TherapyOpen access

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

Francesco Facchinetti, Luc Friboulet

Open full text 17 citations

Abstract

Abstract: ROS1 inhibition provides impressive survival benefits in ROS1 -rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with preliminary proofs of success in this oncogene-driven disease, either in the post-crizotinib setting or as first-line targeted agents. Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. Of interest, in August 2019 entrectinib was granted by FDA accelerated approval for the treatment of ROS1 -rearranged NSCLC, as well as of NTRK-driven solid tumors. Keywords: lung cancer, ROS1, tyrosine kinase inhibitors, entrectinib

Open-access reader

About this research paper

What this paper is about

Abstract: ROS1 inhibition provides impressive survival benefits in ROS1 -rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with preliminary proofs of success in this oncogene-driven disease, either in the post-crizotinib setting or as first-line targeted agents. Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. Of interest, in August 2019 entrectinib was granted by FDA accelerated approval for the treatment of ROS1 -rearranged NSCLC, as well as of NTRK-driven solid tumors. Keywords: lung cancer, ROS1, tyrosine kinase inhibitors, entrectinib

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract: ROS1 inhibition provides impressive survival benefits in ROS1 -rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with preliminary proofs of success in this oncogene-driven disease, either in the post-crizotinib setting or as first-line targeted agents. Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. Of interest, in August 2019 entrectinib was granted by FDA accelerated approval for the treatment of ROS1 -rearranged NSCLC, as well as of NTRK-driven solid tumors. Keywords: lung cancer, ROS1, tyrosine kinase inhibitors, entrectinib

Key concepts: Crizotinib, ROS1, Medicine, Lung cancer, Context (archaeology), ALK inhibitor, Cabozantinib, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date — Research Paper | ScholarLens